Nitto Denko Avecia Inc. (Avecia) announced the opening of its new oligonucleotide API (active pharmaceutical ingredients) manufacturing facility in Milford, MA.
The opening of the manufacturing facility will take place in 2017 onsite at the Milford, MA facility.
This expansion will help Avecia's clients to receive timely oligonucleotide API to advance their drug development programs in clinical trials as planned.
It will add 20,000 square feet of manufacturing and office space at Avecia's Milford, MA site and provide CGMP oligonucleotide manufacturing capacity up to 1.8mol.
The total capacity of Avecia's Milford, MA site has now more than doubled up to 3.0mol, which makes Avecia in Milford, MA the largest oligonucleotide manufacturing site in the world.
Avecia engineers have introduced novel technology that executed expansion in record time, and in close collaboration with A/Z Corporation to ensure the timely supply of novel oligonucleotide therapeutics.
Currently, Avecia has more than 50 open positions at its four locations in MA, OH, and CA. Earlier, it has added more than 120 MA jobs in the last 12 months in Milford, MA.
In addition, the new positions will specialize in microbiology, analytical chemistry, manufacturing, quality assurance and engineering.
|Nitto Denko Avecia Inc. (Avecia)
|20,000 Square Feet